Compare ADMA Biologics Inc (ADMA) vs ADT Inc (ADT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs ADT Inc — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while ADT Inc trades at $7.34 (market cap $5.44B). The key difference: ADT Inc is far larger — about 2.5× ADMA Biologics Inc's market cap, and ADT Inc pays a 2.95% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ADT | |
|---|---|---|
Market Cap | $2.22B | $5.44B |
Sector | Health | Industrials |
52-Week High | $20.38 | $8.85 |
52-Week Low | $7.60 | $6.30 |
Enterprise Value | $2.29B | $13.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
ADT trades at $7.31, down 2.66% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows solid fundamentals with a P/E of 10.35, net income margin of 11.86%, and consistent revenue growth, supported by positive analyst sentiment and institutional buying.
Outlook remains positive due to strong cash flow, dividend payments, and AI integration, but risks include high debt levels and competitive pressures. Wall Street consensus leans bullish with 47% buy ratings, suggesting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →
